Phase II Study of Regorafenib as Maintenance Therapy

  • STATUS
    Recruiting
  • End date
    Apr 26, 2023
  • participants needed
    126
  • sponsor
    Centre Oscar Lambret
Updated on 26 January 2021

Summary

Multicenter double-blind placebo-controlled randomized Phase II study comparing regorafenib to placebo, as maintenance therapy in metastatic soft-tissue non-adipocytic sarcomas experiencing stable disease or response after 6 cycles of doxorubicin-based chemotherapy as 1st line chemotherapy.

Description

Patients will be randomized 1:1 using a centralized randomization software, assuring concealment, with a minimization program controlling for the following factors:

  • Histological subgroups: leiomyosarcoma versus synovial sarcoma versus other histological subtype
  • Response to doxorubicin-based chemotherapy: partial response versus stable disease
  • Centers

The treatment will be administrated as long as it appears beneficial. Evaluations will be made every 8 weeks until 6 months and then every 3 months

Details
Condition Metastatic Soft Tissue Sarcoma
Treatment Placebo, Regorafenib
Clinical Study IdentifierNCT03793361
SponsorCentre Oscar Lambret
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18 years
Histologically proven soft tissue sarcoma including leiomyosarcoma, synovial sarcoma and other sarcomas
Patients in partial response or stable disease after 6 cycles of doxorubicin-based first-line chemotherapy for metastatic/locally advanced soft tissue sarcoma
Metastatic/locally advanced disease not amenable to surgical resection with curative intent
Eastern Cooperative Oncology Group (ECOG) Performance Status =0 or 1
Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by RECIST 1.1
Available tumor tissue for translational research program
Adequate bone marrow, renal, and hepatic function, as evidenced by the following within 7 days of study treatment initiation
Absolute neutrophil count (ANC) 1,500/mm3
Platelets 100,000/mm3
Hemoglobin 9.0 g/dL
Serum creatinine 1.5 x upper limit of normal (ULN)
Glomerular filtration rate (GFR) 30 ml/min/1.73m2
AST and ALT 2.5 x ULN ( 5.0 ULN for patients with liver involvement of their cancer)
Bilirubin 1.5 X ULN
Alkaline phosphatase 2.5 x ULN (5 x ULN with liver involvement of their cancer)
Lipase 1.5 x ULN
Spot urine must not show 1+ or more protein in urine or the patient will require a repeat urine analysis. If repeat urinanalysis shows 1+ protein or more, a 24-hour urine collection will be required and must show total protein excretion <1000 mg/24 hours
INR/PTT 1.5 x ULN (Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care.)
Women of childbearing potential and male subjects must agree to use adequate contraception for the duration of study participation and up to 3 months following completion of therapy. Adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of care
Recovery to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0 Grade 0 or 1 level or recovery to baseline preceding the prior treatment from any previous drug/procedure related toxicity (except alopecia, anemia, and hypothyroidism)
In the assessment of the investigator, patients are able to comply with study requirements
Signed, IRB-approved written informed consent
Patient covered by the French "Social Security" regime

Exclusion Criteria

Prior adjuvant or neoadjuvant chemotherapy not allowing at least 6 cycles of doxorubicin-based chemotherapy at metastatic stage
Complete response to 1st line chemotherapy for metastatic/locally advanced soft tissue sarcoma
Disease progression during the 1st line of chemotherapy
Time interval between the last cycle of doxorubicin-based chemotherapy superior to 8 weeks
Primary bone sarcoma
All forms of liposarcoma
Some particular histologic types, i.e., PNET/Ewing, alveolar or embryonal rhabdomyosarcoma, Perivascular epithelioid cell sarcoma (PECoMA), low grade endometrial stromal tumor, desmoid tumor
Prior treatment with tyrosine kinase inhibitor
Known history of or concomitant malignancy likely to affect life expectancy in the judgment of the investigator
Pregnant or breastfeeding patients. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of Day 1 of treatment
Active cardiac disease including any of the following: Congestive heart failure (New York Heart Association [NYHA]) Class 2, Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months), Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)
Uncontrolled hypertension (Systolic blood pressure >150 mmHg or diastolic pressure >90 mmHg despite optimal medical management)
Arterial or venous thrombotic or embolic events such as myocardial infarction, cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 6 months of starting on study drug
Any hemorrhage or bleeding event > Grade 4 within 4 weeks of start of treatment
Ongoing infection >Grade 2 according to NCI Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v. 5.0)
Known history of human immunodeficiency virus (HIV) infection
Known history of chronic hepatitis B or C
Patients with seizure disorder requiring medication
History of organ allograft
Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event > Grade 4 within 4 weeks of start of treatment
Non-healing wound, ulcer, or bone fracture
Renal failure requiring hemo- or peritoneal dialysis
Dehydration according to NCI-CTC v 4.0 Grade >1
Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Inability to swallow oral medications, Any mal-absorption condition
Pleural effusion or ascites that causes respiratory compromise (Grade 2 dyspnea)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note